Hürthle cell neoplasm

Area of Science:

• Endocrinology
• Surgical Oncology
• Pathology

Background:

• Hürthle cell neoplasms (HNC) of the thyroid are rare and their malignant potential is debated.
• Surgical management strategies for HNC vary, lacking universal consensus.
• Distinguishing benign from malignant HNC is crucial for appropriate treatment.

Purpose of the Study:

• To evaluate the surgical treatment outcomes for Hürthle cell neoplasms.
• To establish criteria for differentiating benign from malignant HNC.
• To determine the optimal surgical approach based on tumor characteristics.

Main Methods:

• Retrospective analysis of 46 patients with HNC who underwent surgery between 1976 and 1986.
• Preoperative diagnosis via fine needle biopsy.
• Surgical procedures included total lobectomy plus isthmusectomy in most cases.
• Histopathological and electron microscopic evaluation for malignancy criteria.

Main Results:

• Hürthle cell carcinoma (HCC) can be distinguished from benign forms by experienced pathologists using invasive malignancy criteria and electron microscopy.
• Lesions smaller than 2 cm were not considered potentially malignant and did not necessitate aggressive surgical treatment.
• Initial treatment with hemithyroidectomy and isthmusectomy was performed, with total thyroidectomy reserved for confirmed malignancy.

Conclusions:

• Hemithyroidectomy and isthmusectomy represent a suitable initial surgical approach for Hürthle cell tumors.
• Histological and electron microscopic examination are essential for diagnosing malignancy and guiding further treatment.
• Tumor size greater than 2 cm is not a definitive indicator of malignancy in HNC.